Fasting Bioequivalence Study of 2 Progesterone Soft Capsules 200 mg in 66 Healthy Female Subjects Under Vaginal Route
Status:
Completed
Trial end date:
2019-10-21
Target enrollment:
Participant gender:
Summary
This study was designed to assess the bioequivalence of Progesterone 200 mg Soft Capsule (JSC
"Farmak", Ukraine) versus Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L.,
Spain, MAH: Laboratoires Besins International, France) after a single Vaginal dose in healthy
female subjects under fasting conditions.